Physician profile
Eric Harris
NPI 1902068158
$96,968.02
in general payments reported to CMS, 2019-2025
84 companies · $3,298 in 2025
The $3,298 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $14K · 2021: $23K · 2022: $8,656 · 2023: $2,886 · 2024: $2,664 · 2025: $3,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,513 · Education: $169 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,513.29 |
| Education | $168.98 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $44,977.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $22,157.85 | 2019-2025 | Opdivo |
| Gilead Sciences, INC. | $13,732.12 | 2021-2025 | Trodelvy |
| Immunomedics, INC. | $2,500.00 | 2020 | |
| Celgene Corporation | $1,339.17 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $1,201.84 | 2019-2025 | Tukysa, Adcetris, Tivdak |
| Rigel Pharmaceuticals, INC. | $1,014.26 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $830.99 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals Lp | $748.33 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Pfizer INC. | $636.31 | 2019-2025 | |
| Janssen Biotech, INC. | $606.86 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Genentech USA, INC. | $455.79 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Bayer Healthcare Pharmaceuticals INC. | $319.53 | 2019-2025 | |
| Abbvie INC. | $313.84 | 2019-2025 | |
| Daiichi Sankyo INC. | $297.75 | 2019-2025 | Enhertu, Datroway, Vanflyta |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $293.11 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Lilly USA, LLC | $285.02 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $270.63 | 2019-2025 | |
| Eisai INC. | $256.24 | 2019-2024 | |
| Exelixis INC. | $247.38 | 2020-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $224.74 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $220.68 | 2019-2025 | Libtayo, Lynozyfic |
| Amgen INC. | $216.91 | 2019-2023 | Lumakras |
| Astellas Pharma US INC | $209.01 | 2019-2025 | Vyloy, Padcev, Xospata |
| Pharmacosmos Therapeutics INC. | $187.65 | 2022-2025 | Monoferric, Cosela |
| Tersera Therapeutics LLC | $185.76 | 2023-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $170.42 | 2019-2025 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $160.09 | 2019-2025 | Bavencio |
| Taiho Oncology, INC. | $147.24 | 2019-2025 | |
| Beigene USA, INC. | $142.88 | 2022-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $142.82 | 2019-2025 | Zepzelca |
| Array Biopharma INC | $136.29 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Kite Pharma, INC. | $134.54 | 2022-2025 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.97 | 2019-2025 | Gilotrif |
| Sobi, INC | $117.19 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.36 | 2022-2025 | Fruzaqla |
| Foundation Medicine, INC. | $112.83 | 2019-2023 | |
| Galvanize Therapeutics, INC | $102.90 | 2025 | Aliya System |
| Puma Biotechnology, INC. | $101.16 | 2022-2024 | Nerlynx |
| Alexion Pharmaceuticals, INC. | $82.77 | 2023-2025 | Ultomiris |
| Mirati Therapeutics, INC. | $81.61 | 2023-2024 | Krazati |
| Dendreon Pharmaceuticals LLC | $79.20 | 2020-2025 | Provenge |
| Sanofi-Aventis U.S. LLC | $76.95 | 2019-2020 | |
| Tesaro, INC. | $71.90 | 2019 | |
| Geron Corporation | $59.70 | 2025 | Rytelo |
| Beone Medicines USA, INC. | $58.76 | 2025 | Brukinsa, Tevimbra |
| Lexicon Pharmaceuticals, INC. | $57.52 | 2019-2020 | |
| Heron Therapeutics, INC. | $57.08 | 2019-2020 | |
| Pharmaessentia USA Corporation | $56.87 | 2022-2024 | Besremi |
| Stemline Therapeutics INC. | $53.60 | 2024-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $52.14 | 2024-2025 | |
| G1 Therapeutics, INC. | $52.01 | 2022-2023 | Cosela |
| Agios Pharmaceuticals, INC. | $47.58 | 2019-2025 | Pyrukynd |
| Secura Bio, INC. | $43.29 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $40.63 | 2019-2020 | |
| Csl Behring | $39.05 | 2023-2024 | Afstyla, Idelvion |
| Legend Biotech USA INC. | $35.70 | 2025 | Carvykti |
| Clovis Oncology, INC. | $35.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.78 | 2024 | Xarelto |
| Cti Biopharma Corp. | $29.91 | 2022-2023 | Vonjo |
| Genmab U.S., INC. | $29.59 | 2025 | Epkinly |
| Recordati_rare_diseases_inc. | $29.26 | 2023 | Sylvant |
| Alnylam Pharmaceuticals INC. | $27.42 | 2024 | Givlaari |
| Aurobindo Pharma USA, INC. | $26.77 | 2019-2020 | |
| Horizon Therapeutics Plc | $26.02 | 2019 | |
| Blueprint Medicines Corporation | $25.31 | 2024 | Ayvakit |
| Nuvation Bio INC. | $22.61 | 2025 | Ibtrozi |
| Adaptive Biotechnologies Corporation | $22.48 | 2023 | Clonoseq |
| Emmaus Medical, INC. | $18.00 | 2019 | |
| Global Blood Therapeutics, INC. | $17.95 | 2022 | |
| Morphosys, US INC. | $17.59 | 2022 | |
| Eusa Pharma (US) LLC | $16.62 | 2019 | |
| Coherus Oncology, INC. | $16.51 | 2024 | |
| Abbott Laboratories | $16.01 | 2024 | Freestyle Libre 3 |
| Syndax Pharmaceuticals, INC. | $15.85 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $15.69 | 2019 | |
| Karyopharm Therapeutics INC. | $14.15 | 2025 | Xpovio |
| Springworks Therapeutics, INC. | $14.05 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $10.94 | 2019 | |
| Veracyte, INC. | $3.08 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.